The US regulator has approved a drug to treat low potassium as the first generic with the Competitive Generic Therapy (CGT) designation, marking the beginning of a new strategy and FDA effo
There are concerns that launch of Teva’s migraine drug may be delayed because of issues uncovered by the FDA at a manufacturing plant run by South Korea’s Celltrion.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
